Inici
→
Recerca
→
Articles, congressos, llibres
→
Articles
→
Consulteu Articles per autor

Consulteu Articles per autor "Van Cutsem, Eric"

Ara es mostren els elements 1-5 de 5

Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study

Tabernero, Josep; Hozak, R.R.; Yoshino, Takayuki; Cohn, A.L.; Obermannova, R.; Bodoky, G.; Garcia Carbonero, R.; Ciuleanu, T.E.; Portnoy, D.C.; Prausova, J.; Van Cutsem, Eric (Elsevier, 2018)

Background: The phase III RAISE trial (NCT01183780) demonstrated that the vascular endothelial growth factor (VEGF) receptor (VEGFR)-2 binding monoclonal antibody ramucirumab plus 5-fluororuracil, leucovorin, and irinotecan ...
Binimetinib Encorafenib and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study

Van Cutsem, Eric; Huijberts, Sanne; Grothey, Axel; Yaeger, Rona; Cuyle, Pieter-Jan; Elez, Elena; Fakih, Marwan; Montagut, Clara; Peeters, Marc; Yoshino, Takayuki; Kopetz, Scott; Tabernero, Josep (Lippincott Williams & Wilkins, 2019)

To determine the safety and preliminary efficacy of selective combination targeted therapy for BRAF V600E-mutant metastatic colorectal cancer (mCRC) in the safety lead-in phase of the open-label, randomized, three-arm, ...
Efficacy and Safety of Pembrolizumab or Pembrolizumab plus Chemotherapy vs Chemotherapy Alone for Patients with First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial

Shitara, Kohei; Van Cutsem, Eric; Bang, Yung-Jue; Fuchs, Charles; Wyrwicz, Lucjan; Tabernero, Josep (American Medical Association, 2020)

IMPORTANCE Safe and effective therapies for untreated, advanced gastric/gastroesophageal junction (G/GEJ) cancer remain an unmet need. OBJECTIVE To evaluate the antitumor activity of pembrolizumab, pembrolizumab plus ...
Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: Updated survival results and subgroup analyses from the BEACON study

Tabernero, Josep; Grothey, Axel; Van Cutsem, Eric; Wasan, Harpreet; Yoshino, Takayuki; Desai, Jayesh; Ciardiello, Fortunato; Loupakis, Fotio; Hong, Yong Sang (American Society of Clinical Oncology, 2021)

PURPOSE BEACON CRC evaluated encorafenib plus cetuximab with or without binimetinib versus investigators' choice of irinotecan or FOLFIRI plus cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC), ...
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer

Kopetz, Scott; Grothey, Axel; Yaeger, Rona; Van Cutsem, Eric; Desai, Jayesh; Yishino, Takayuki; Wasan, Harpreet; Ciardiello, Fortunato; Loupakis, Fotio; Tabernero, Josep (Massachusetts Medical Society, 2019)

Colorectal cancers with BRAF mutations have an aggressive natural history and are often resistant to therapy. A treatment regimen that combined BRAF inhibition, MET inhibition, and blocking of EGFR signaling resulted in a ...

Ara es mostren els elements 1-5 de 5

Buscar al RIUVic

Llistar per

Tot el repositori
Aquesta col·lecció

Consulteu Articles per autor "Van Cutsem, Eric"

Consulteu Articles per autor "Van Cutsem, Eric"

Buscar al RIUVic

Llistar per

Tot el repositori

Aquesta col·lecció